Identification of GPC2 as an Oncoprotein and Candidate Immunotherapeutic Target in High-Risk NeuroblastomaKristopher R. Bosse, John M. Maris, Maria Lane et al.|Cancer Cell|2017Cited by 229
Wnt pathway activation by ADP-ribosylationEungi Yang, Yashi Ahmed, Ofelia Tacchelly‐Benites et al.|Nature Communications|2016Cited by 73
Germline pathogenic variants in neuroblastoma patients are enriched in <i>BARD1</i> and predict worse survivalJung Kim, Sharon J. Diskin, Zalman Vaksman et al.|JNCI Journal of the National Cancer Institute|2023Cited by 28
Pembrolizumab + GVD with ctdna-guided consolidation for relapsed/refractory classic Hodgkin lymphoma: A multicenter phase 2 Study of the University of California hematologic malignancies consortiumMichael P. Randall, Michael A. Spinner, Wendy Swetzig Dhiman et al.|Blood|2025Cited by 1
527 | HIGH‐THROUGHPUT T CELL RECEPTOR SEQUENCING TO DETECT MEASURABLE RESIDUAL DISEASE IN SYSTEMIC T CELL LYMPHOMA TREATED WITH BRENTUXIMAB VEDOTIN: A PROSPECTIVE TRIALMichael P. Randall, Weiyun Z. Ai, Zachary R. Barbati et al.|Hematological Oncology|2025Cited by 0